Hanmi Pharm (128940 KS/Buy)Roche’s Answer to Eli Lilly and Novo Nordisk
Our target price for Hanmi Pharm is based on an operating value estimate of W5.2tr and a pipeline value estimate of W4.3tr (vs. W3.1tr previously).
87 Views
Hanmi Pharm (128940 KS/Buy)Focus on Beijing Hanmi’s Recovery and Pipeline Progress
Focus on Beijing Hanmi’s recovery and pipeline progressMaintain Buy; lower TP to W640,000 (from W700,000) Our target price for Hanmi Pharm is...
100 Views
Hanmi Pharma (128940 KS Oct 28, 2025) - Hunting the KOSPI Obesity Leader
Hanmi unveiled phase 3 trial results for next-gen obesity drug efpeglenatide Fewer side effects, better affordability; a practical obesity...
493 Views
[2H26 Outlook] Pharma/BiotechCatalysts for a biotech rebound
Biotech stocks performed well early this year, driven by optimism surrounding the government's KOSDAQ 3,000 target and supportive fund flows...
116 Views
Hanmi Pharma (128940 KS Jul 28, 2025) - Earnings Recovery in Progress
2Q25 consolidated revenue W361.3bn (-4.5% YoY), OP W60.4bn (+3.9% YoY). High-margin product mix should continue driving profitability; subsidiary...
204 Views